Fixed-Dose DPP-4 Inhibitor and Metformin Combinations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 2 diabetes often require complex regimens involving multiple oral antidiabetic drugs, which can be difficult for patients to manage, and there is a need for a combination therapy that simplifies medication administration while maintaining effective glycemic control.
Innovation Solution
Development of pharmaceutical compositions in the form of fixed-dose combinations of DPP-4 inhibitors, such as sitagliptin, vildagliptin, or saxagliptin, with metformin hydrochloride, prepared using dry or wet processing methods, resulting in immediate-release tablets that combine these active ingredients in a single dosage form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple oral antidiabetic drugs are co-prescribed, then glycemic control effectiveness is improved, but treatment regimen complexity increases
Solution Approach 1:
The patent combines multiple oral antidiabetic drugs (metformin and a second antidiabetic agent) into a single fixed-dose combination tablet. This merging of multiple medications into one dosage form directly reduces treatment regimen complexity while maintaining the therapeutic effectiveness of each component drug for glycemic control.
Solution Approach 2:
The single tablet formulation serves multiple functions simultaneously: it delivers metformin for its primary antidiabetic effect, includes a second antidiabetic agent for complementary glycemic control, and provides a simplified administration regimen. This multi-functionality in one dosage form addresses both effectiveness and complexity concerns.
2Reliability
If multiple oral antidiabetic drugs are co-prescribed, then glycemic control effectiveness is improved, but patient compliance deteriorates
Solution Approach 1:
By merging multiple antidiabetic medications into a single fixed-dose combination tablet, the invention simplifies the patient's daily medication routine from taking multiple separate pills to taking one tablet, thereby improving compliance while preserving the therapeutic benefits of combination therapy.
3Reliability
If combination therapy is implemented, then treatment efficacy is improved, but regimen complexity increases
Solution Approach 1:
The fixed-dose combination tablet merges multiple antidiabetic agents into one unified dosage form, allowing combination therapy to be administered through a single tablet rather than multiple separate medications, thus maintaining treatment efficacy while reducing regimen complexity.
Data Source
AI summary
Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.